Dominik Berzaczy1, Barbara Fueger2, Christoph Hoeller3, Alexander R Haug4,5, Anton Staudenherz4,6, Gundula Berzaczy2, Michael Weber2, Marius E Mayerhoefer2,7. 1. Department of Biomedical Imaging and Image-guided Therapy, Division of General and Pediatric Radiology, Medical University of Vienna, Vienna, Austria. dominik.berzaczy@meduniwien.ac.at. 2. Department of Biomedical Imaging and Image-guided Therapy, Division of General and Pediatric Radiology, Medical University of Vienna, Vienna, Austria. 3. Department of Dermatology, Medical University of Vienna, Vienna, Austria. 4. Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria. 5. Christian Doppler Laboratory for Applied Metabolomics, Medical University of Vienna, Vienna, Austria. 6. Department of Nuclear Medicine, Molecular Imaging and Special Endocrinology, University Hospital St. Pölten, Karl Landsteiner University of Health Science, St. Pölten, Austria. 7. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
Abstract
PURPOSE: To assess the diagnostic performance of simultaneous whole-body 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) positron emission tomography (PET)/magnetic resonance imaging (MRI) compared to [18F]FDG PET/x-ray computed tomography (CT) for detection of distant metastatic disease in patients with malignant melanoma. PROCEDURES: We included patients with malignant melanoma who underwent a single injection [18F]FDG dual-imaging protocol that included whole-body PET/CT and subsequent whole-body PET/MRI for staging or restaging purposes in a prospective setting. Images from both modalities were analyzed by two rater teams for the presence of metastatic lesions. PET/CT-PET/MRI overall agreement as well as region-based accuracies, sensitivities (Se), and specificities (Sp) were computed. RESULTS: Between July 2014 and December 2018, 22 patients were enrolled. Interrater agreement and overall accuracy (consensus reading) were 78.8 % (95 % CI 71-84.9) and 96.1 % (95 % CI 92.3-98) for PET/MRI and 78 % (70.2-84.3) and 97.4 % (95 % CI 93.7-98.9) for PET/CT, respectively (P = 0.42). PET/MRI reached a region-based Se of 89.1 % (95 % CI 79.4-94.5) and a Sp of 100 %, whereas PET/CT showed a region-based Se of 92.7 % (95 % CI 84-96.9) and a Sp of 100 % for the detection of metastatic disease in malignant melanoma. CONCLUSIONS: Whole-body [18F]FDG-PET/MRI appears to be comparable to [18F]FDG-PET/CT for lesion detection in patients with malignant melanoma.
PURPOSE: To assess the diagnostic performance of simultaneous whole-body 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) positron emission tomography (PET)/magnetic resonance imaging (MRI) compared to [18F]FDG PET/x-ray computed tomography (CT) for detection of distant metastatic disease in patients with malignant melanoma. PROCEDURES: We included patients with malignant melanoma who underwent a single injection [18F]FDG dual-imaging protocol that included whole-body PET/CT and subsequent whole-body PET/MRI for staging or restaging purposes in a prospective setting. Images from both modalities were analyzed by two rater teams for the presence of metastatic lesions. PET/CT-PET/MRI overall agreement as well as region-based accuracies, sensitivities (Se), and specificities (Sp) were computed. RESULTS: Between July 2014 and December 2018, 22 patients were enrolled. Interrater agreement and overall accuracy (consensus reading) were 78.8 % (95 % CI 71-84.9) and 96.1 % (95 % CI 92.3-98) for PET/MRI and 78 % (70.2-84.3) and 97.4 % (95 % CI 93.7-98.9) for PET/CT, respectively (P = 0.42). PET/MRI reached a region-based Se of 89.1 % (95 % CI 79.4-94.5) and a Sp of 100 %, whereas PET/CT showed a region-based Se of 92.7 % (95 % CI 84-96.9) and a Sp of 100 % for the detection of metastatic disease in malignant melanoma. CONCLUSIONS: Whole-body [18F]FDG-PET/MRI appears to be comparable to [18F]FDG-PET/CT for lesion detection in patients with malignant melanoma.
Authors: Annette Pflugfelder; Corinna Kochs; Andreas Blum; Marcus Capellaro; Christina Czeschik; Therese Dettenborn; Dorothee Dill; Edgar Dippel; Thomas Eigentler; Petra Feyer; Markus Follmann; Bernhard Frerich; Maria-Katharina Ganten; Jan Gärtner; Ralf Gutzmer; Jessica Hassel; Axel Hauschild; Peter Hohenberger; Jutta Hübner; Martin Kaatz; Ulrich R Kleeberg; Oliver Kölbl; Rolf-Dieter Kortmann; Albrecht Krause-Bergmann; Peter Kurschat; Ulrike Leiter; Hartmut Link; Carmen Loquai; Christoph Löser; Andreas Mackensen; Friedegund Meier; Peter Mohr; Matthias Möhrle; Dorothee Nashan; Sven Reske; Christian Rose; Christian Sander; Imke Satzger; Meinhard Schiller; Heinz-Peter Schlemmer; Gerhard Strittmatter; Cord Sunderkötter; Lothar Swoboda; Uwe Trefzer; Raymond Voltz; Dirk Vordermark; Michael Weichenthal; Andreas Werner; Simone Wesselmann; Ansgar J Weyergraf; Wolfgang Wick; Claus Garbe; Dirk Schadendorf Journal: J Dtsch Dermatol Ges Date: 2013-08 Impact factor: 5.584